company background image
SDPC

Millennium Pharmacon International IDX:SDPC Stock Report

Last Price

Rp129.00

Market Cap

Rp164.3b

7D

0.8%

1Y

0%

Updated

19 May, 2022

Data

Company Financials
SDPC fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance4/6
Financial Health3/6
Dividends1/6

SDPC Stock Overview

PT Millennium Pharmacon International Tbk engages in the distribution and trading of prescription and non-prescription medicines, dietary supplements, and medical devices in Indonesia.

Millennium Pharmacon International Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Millennium Pharmacon International
Historical stock prices
Current Share PriceRp129.00
52 Week HighRp214.00
52 Week LowRp107.00
Beta0.51
1 Month Change7.50%
3 Month Change-3.01%
1 Year Change0%
3 Year Change22.86%
5 Year Change5.74%
Change since IPO637.14%

Recent News & Updates

Shareholder Returns

SDPCID HealthcareID Market
7D0.8%3.4%-1.0%
1Y0%16.8%18.2%

Return vs Industry: SDPC underperformed the ID Healthcare industry which returned 16.8% over the past year.

Return vs Market: SDPC underperformed the ID Market which returned 18.2% over the past year.

Price Volatility

Is SDPC's price volatile compared to industry and market?
SDPC volatility
SDPC Average Weekly Movement6.3%
Healthcare Industry Average Movement5.5%
Market Average Movement6.3%
10% most volatile stocks in ID Market12.2%
10% least volatile stocks in ID Market3.0%

Stable Share Price: SDPC is not significantly more volatile than the rest of ID stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: SDPC's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19521,075Ahmad Bin Abu Bakarhttps://www.mpi-indonesia.co.id

PT Millennium Pharmacon International Tbk engages in the distribution and trading of prescription and non-prescription medicines, dietary supplements, and medical devices in Indonesia. The company distributes its products through drug stores, pharmacies, hospitals, supermarkets, and retail shops. As of December 31, 2021, it operated 33 branch offices in Java, Bali, Sumatera, Kalimantan, and Sulawesi Islands.

Millennium Pharmacon International Fundamentals Summary

How do Millennium Pharmacon International's earnings and revenue compare to its market cap?
SDPC fundamental statistics
Market CapRp164.35b
Earnings (TTM)Rp9.57b
Revenue (TTM)Rp2.99t

17.2x

P/E Ratio

0.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SDPC income statement (TTM)
RevenueRp2.99t
Cost of RevenueRp2.75t
Gross ProfitRp237.04b
Other ExpensesRp227.47b
EarningsRp9.57b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)7.51
Gross Margin7.93%
Net Profit Margin0.32%
Debt/Equity Ratio200.4%

How did SDPC perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

7%

Payout Ratio

Valuation

Is Millennium Pharmacon International undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


17.17x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: SDPC (IDR129) is trading above our estimate of fair value (IDR5.21)

Significantly Below Fair Value: SDPC is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SDPC is good value based on its PE Ratio (17.2x) compared to the ID Healthcare industry average (19.9x).

PE vs Market: SDPC is good value based on its PE Ratio (17.2x) compared to the ID market (18.9x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SDPC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SDPC is good value based on its PB Ratio (0.7x) compared to the ID Healthcare industry average (1.9x).


Future Growth

How is Millennium Pharmacon International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


16.7%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Millennium Pharmacon International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Millennium Pharmacon International performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-21.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SDPC has high quality earnings.

Growing Profit Margin: SDPC's current net profit margins (0.3%) are higher than last year (0.1%).


Past Earnings Growth Analysis

Earnings Trend: SDPC's earnings have declined by 21.5% per year over the past 5 years.

Accelerating Growth: SDPC's earnings growth over the past year (241.3%) exceeds its 5-year average (-21.5% per year).

Earnings vs Industry: SDPC earnings growth over the past year (241.3%) exceeded the Healthcare industry 121.6%.


Return on Equity

High ROE: SDPC's Return on Equity (4%) is considered low.


Financial Health

How is Millennium Pharmacon International's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: SDPC's short term assets (IDR1,070.3B) exceed its short term liabilities (IDR942.6B).

Long Term Liabilities: SDPC's short term assets (IDR1,070.3B) exceed its long term liabilities (IDR26.8B).


Debt to Equity History and Analysis

Debt Level: SDPC's net debt to equity ratio (180.4%) is considered high.

Reducing Debt: SDPC's debt to equity ratio has reduced from 206.5% to 200.4% over the past 5 years.

Debt Coverage: SDPC's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: SDPC's interest payments on its debt are not well covered by EBIT (1.4x coverage).


Balance Sheet


Dividend

What is Millennium Pharmacon International current dividend yield, its reliability and sustainability?

Dividend Score

1/6

Dividend Score 1/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


0.39%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: SDPC's dividend (0.39%) isn’t notable compared to the bottom 25% of dividend payers in the ID market (1.12%).

High Dividend: SDPC's dividend (0.39%) is low compared to the top 25% of dividend payers in the ID market (4.1%).


Stability and Growth of Payments

Stable Dividend: SDPC has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: SDPC has only been paying a dividend for 6 years, and since then payments have fallen.


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (6.7%), SDPC's dividend payments are thoroughly covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: SDPC is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Ahmad Bin Abu Bakar (52 yo)

1.75yrs

Tenure

Mr. Ahmad Bin Abu Bakar serves as President Director at PT Millennium Pharmacon International Tbk since August 2020. He has been a Director at PT Millennium Pharmacon International TBK. since September 29,...


Leadership Team

Experienced Management: SDPC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: SDPC's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PT Millennium Pharmacon International Tbk's employee growth, exchange listings and data sources


Key Information

  • Name: PT Millennium Pharmacon International Tbk
  • Ticker: SDPC
  • Exchange: IDX
  • Founded: 1952
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Implied Market Cap: Rp164.346b
  • Shares outstanding: 1.27b
  • Website: https://www.mpi-indonesia.co.id

Number of Employees


Location

  • PT Millennium Pharmacon International Tbk
  • Crown Bungur Arteri
  • 2-4th Floors
  • Jakarta Selatan
  • Jakarta Raya
  • 12220
  • Indonesia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/19 00:00
End of Day Share Price2022/05/19 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.